SCHEMBL527040

SCHEMBL527040

Cc1ccncc1-c1ccc(N(C)S(=O)(=O)c2ccccc2)cc1

nearest known ligand 0.52

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NR1I2 O75469 1/20 0.50
CA12 O43570 1/20 0.49
CA9 Q16790 1/20 0.49
CYP11B1 P15538 1/20 0.47
CYP11B2 P19099 1/20 0.47
NAMPT P43490 1/20 0.46
MAPT P10636 1/20 0.45
MCOLN3 Q8TDD5 1/20 0.45
PTGS2 P35354 1/20 0.44
NR1H2 P55055 3/20 0.44
NR1H3 Q13133 3/20 0.44
GAA P10253 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.43
PTGES2 Q9H7Z7 1/20 0.43
DHODH Q02127 1/20 0.43
HSD17B1 P14061 1/20 0.42
HSD17B2 P37059 1/20 0.42
PGR P06401 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27928346 0.75 DHODH (0.46) CYP11B1CYP11B2PTGS2DHODH
SCHEMBL10205412 0.74 CYP17A1 (0.58) CYP11B1CYP11B2PTGES2DHODH
SCHEMBL9959448 0.74 CA12 (0.56) NR1I2CA12CA9CYP11B1CYP11B2
SCHEMBL11910521 0.73 CA12 (0.86) NR1I2CA12CA9MAPTMCOLN3
SCHEMBL812702 0.73 CA12 (0.78) NR1I2CA12CA9MAPTMCOLN3
SCHEMBL526742 0.72 PTGS2 (0.45) PTGS2PTGES2
SCHEMBL526867 0.71 CYP17A1 (0.53) PTGS2PTGES2DHODH
SCHEMBL5136325 0.70 NR1I2 (0.55) NR1I2CA12CA9MAPTMCOLN3
SCHEMBL526361 0.70 UQCRB (0.58) CA12CA9CYP11B1CYP11B2MAPT
SCHEMBL6794824 0.70 CA12 (0.73) NR1I2CA12CA9MAPTMCOLN3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2598481-A1 SULFONAMIDE COMPOUNDS USEFUL AS CYP17 INHIBITORS Bristol-Myers Squibb Company (US) 2013-06-05 EP disclosed
WO-2012015723-A1 SULFONAMIDE COMPOUNDS USEFUL AS CYP17 INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2012-02-02 WO disclosed